In breast cancer cells, nuclear EGFR inhibits NK cell recruitment and cytotoxicity, while treatment with cSNX1.3 significantly improves NK cell recruitment and cytotoxicity, although this newly discovered mechanism requires further in‐depth exploration.[354]. Here, EGFR is linked to breast carcinoma.